MedTrace Logo

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

NCT00315640 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.

Conditions

  • Eye Diseases

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 6 mg/mL

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

DRUG

Anecortave Acetate Suspension Depot, 30 mg/mL

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

OTHER

Anecortave Acetate Vehicle

One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States
  • Brazil
  • Hungary
  • Italy
  • Netherlands
  • Puerto Rico
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00315640 on ClinicalTrials.gov